Zhuo-Fei Bi
Overview
Explore the profile of Zhuo-Fei Bi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
100
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Liu G, Xia W, Bi Z, Lu N, Li W, Bei W, et al.
Front Oncol
. 2022 Jun;
12:860700.
PMID: 35756638
Background: Plasma Epstein-Barr virus DNA (EBV-DNA) is a sensitive and specific biomarker for nasopharyngeal carcinoma (NPC). We investigated whether longitudinal monitoring of EBV-DNA could accurately detect clinical disease progression in...
3.
You K, Bi Z, Ma Y, Mao Y, Zou W, Liu Y, et al.
Cancer Control
. 2021 Feb;
28:1073274821997426.
PMID: 33626920
Purpose: Although breast conservation surgery(BCS) followed by adjuvant radiotherapy is now the mainstream treatment method for breast ductal carcinoma in situ(DCIS), mastectomy is still performed in some patients who refuse...
4.
You K, Zou W, Ding L, Bi Z, Yao H
Cancer Manag Res
. 2021 Feb;
13:1325-1332.
PMID: 33603478
Purpose: The optimum timing of adjuvant radiotherapy for breast cancer patients who had undergone surgery remains unclear. The present study aimed to identify the clinical factors which could assist the...
5.
Ding L, Bi Z, Yuan H, Zhao X, Guan X, Yao H, et al.
Laryngoscope
. 2020 Nov;
131(2):E489-E499.
PMID: 33135805
Objectives: To characterize sarcomatoid cell carcinoma (SaC) in head and neck, explore the value of radiotherapy (RT) and chemotherapy, and build a nomogram to predict the prognosis. Study Design: Retrospective...
6.
You K, Bi Z, Ding L, Ma Y, Liu Y, Yao H
Cancer Manag Res
. 2020 Oct;
12:9211-9219.
PMID: 33061612
Background: Due to the low rate of regional recurrence (RR) in early-stage breast cancer with pT1-2 and negative sentinel lymph node biopsy (SLNB), no regional therapy is suggested for them....
7.
You K, Peng H, Jiang Y, Bi Z, Qiu X
Cancer Manag Res
. 2019 Jun;
11:4815-4823.
PMID: 31213903
Whether concurrent chemotherapy could bring about better oncological outcomes in elderly patients receiving definitive radiotherapy is still unknown. So, the purpose of this study was to find out whether it...
8.
Zhao X, Wang Z, Chen C, Di L, Bi Z, Li Z, et al.
World J Gastroenterol
. 2019 Jan;
25(1):138-150.
PMID: 30643364
Aim: To evaluate the clinical properties of three subpopulations of circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) patients. Methods: We identified CTCs for expression...
9.
Chen W, Weng S, Lv M, Chen W, Bi Z, Chen H, et al.
Cell Physiol Biochem
. 2018 Dec;
51(5):2019-2029.
PMID: 30522107
Background/aims: β-Elemene is a bioactive sesquiterpene compound that exhibits a potent anti-tumor effect and is used in various clinical applications. However, little is known about its effect on the male...
10.
You K, Zhou X, Jiang Y, Bi Z, Liu Y, Qiu X
Int J Gynecol Cancer
. 2018 Aug;
28(7):1325-1332.
PMID: 30074519
Objectives: The optimal interval between surgery and adjuvant treatment has not yet been found in cervical cancer. And whether patients with different FIGO stage should choose different interval is unknown....